IP Library Patent Application 17598058
Patent Application
App. No. 17/598,058

GAS DELIVERY SYSTEM

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/598,058
Abstract

A gas delivery system is provided. The gas delivery system includes a pump operable to receive blood from a patient. A gas transfer unit is in fluid communication with the pump and operable to receive the blood from the pump and deliver a therapeutic amount of xenon gas to the blood. A patient connector withdraws and/or infuses the blood into the patient.

Claims (49)

1 . A gas delivery system for delivering xenon gas to a patient, the gas delivery system comprising:

a pump operable to receive blood from a patient;

a gas transfer unit in fluid communication with the pump and operable to receive the blood from the pump and deliver a therapeutic amount of xenon gas to the blood; and

a patient connector operable to withdraw and/or infuse the blood into the patient.

2 . The gas delivery system of claim 1 , wherein the patient is awake.

3 . The gas delivery system of claim 1 , wherein the patient is non-intubated.

4 . The gas delivery system of claim 1 , further comprising:

a first gas detection sensor located upstream from the gas transfer unit and operable to measure a first concentration of the xenon in the blood prior to passing through the gas transfer unit; and

a second gas detection sensor located downstream from the gas transfer unit and operable to measure a second concentration of xenon in the blood after passing through the gas transfer unit.

5 . The gas delivery system of claim 4 , further comprising: a controller coupled with the gas transfer unit, the first gas detection sensor, and the second gas detection sensor, the controller being operable to:

receive the first concentration of xenon from the first gas detection sensor;

receive the second concentration of xenon from the second gas detection sensor;

compare the first concentration and the second concentration;

determine, when the first concentration is less than the second concentration gas, an additional amount of xenon gas to be delivered to the blood; and

adjust, when the first concentration is less than the second concentration, the gas transfer unit to deliver the additional amount of xenon to the blood such that the blood includes the therapeutic amount of xenon.

6 . The gas delivery system of claim 5 , wherein the controller automatically determines the additional amount of xenon gas to be delivered to the blood.

7 . The gas delivery system of claim 1 , wherein the gas transfer unit is further operable to deliver a predetermined amount of oxygen gas to the blood.

8 . The gas delivery system of claim 1 , wherein the gas transfer unit is included in an extracorporeal membrane oxygenation (ECMO) system.

9 . The gas delivery system of claim 1 , wherein the pump includes a centrifugal pump.

10 . The gas delivery system of claim 1 , wherein the patient connector further includes:

a first conduit in fluidic communication with the pump and the gas transfer unit operable to be inserted into the patient to withdraw the blood;

a second conduit in fluidic communication with the pump and the gas transfer unit operable to be inserted into the patient such that the blood is infused into the patient.

11 . The gas delivery system of claim 10 , wherein the first conduit is operable to be inserted into and be in fluidic communication with a vein of the patient, and the second conduit is operable to be inserted into and be in fluidic communication with an artery of the patient.

12 . The gas delivery system of claim 1 , further comprising:

a temperature unit operable to maintain the blood at a predetermined temperature.

13 . A method of preventing or inhibiting reperfusion injury in a patient with ischemia, the method comprising:

withdrawing blood from a patient;

pumping the withdrawn blood through a gas transfer unit;

delivering, by the gas transfer unit, a therapeutic amount of xenon gas to the withdrawn blood; and

pumping the blood from the gas transfer unit to the patient.

14 . The method of claim 13 , wherein the patient is awake.

15 . The method of claim 13 , wherein the patient is non-intubated.

16 . The method of claim 13 , further comprising:

measuring, by a first gas detection sensor, a first concentration of the xenon in the blood prior to passing through the gas transfer unit; and

measuring, by a second gas detection sensor, a second concentration of xenon in the blood after passing through the gas transfer unit.

17 . The method of claim 16 , further comprising:

comparing, by a controller, the first concentration and the second concentration;

determining, by the controller when the first concentration is less than the second concentration, an additional amount of xenon gas to be delivered to the blood;

adjusting, by the controller when the first concentration is less than the second concentration, the gas transfer unit to deliver the additional amount of xenon to the blood such that the blood includes the therapeutic amount of xenon gas.

18 . The method of claim 17 , further comprising:

wherein the controller automatically determines the additional amount of xenon gas to be delivered to the blood.

19 . The method of claim 13 , further comprising:

delivering a predetermined amount of oxygen gas to the blood.

20 . The method of claim 13 , wherein the gas transfer unit is included in an extracorporeal membrane oxygenation (ECMO) system.

21 . The method of claim 13 , wherein the pump includes a centrifugal pump.

22 . The method of claim 13 , further comprising:

inserting a first conduit into the patient to withdraw the blood; and

inserting a second conduit into the patient to infuse the blood into the patient.

23 . The method of claim 19 , wherein the first conduit is operable to be inserted into and be in fluidic communication with a vein of the patient, and the second conduit is operable to be inserted into and be in fluidic communication with an artery of the patient.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2022
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 059387/0571 →
CHANGE OF NAME Recorded Mar 24, 2022
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
Reel/Frame 059496/0386 →
CONFIDENTIALITY AGREEMENT Recorded Mar 24, 2022
From: POTENZIANO, JAMES
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 059496/0371 →